吉非替尼治疗56例晚期非小细胞肺癌的临床观察  

Clinical observation of gefitinib for 56 patients with advanced non-small cell lung cancer

作　　者：李卫东[1] 李金瀚[2] 谢剑明[2] 尤长宣[2] 罗荣城[2] 

机构地区：[1]广州医学院附属肿瘤医院化疗二科,广州510095 [2]南方医科大学南方医院肿瘤中心,510515

出　　处：《临床肿瘤学杂志》2009年第7期631-633,共3页Chinese Clinical Oncology

摘　　要：目的：探讨晚期非小细胞肺癌（NSCLC）患者应用吉非替尼治疗的效果及毒副反应。方法：回顾2003年1月～2008年12月应用吉非替尼治疗的晚期NSCLC有随访资料的患者56例，其中一线治疗5例，二线或三线治疗51例，对其疗效、毒副反应及生存期进行分析。结果：全组56例，PR12例，占21．4％；SD20例，占35．7％；PD24例，占42．9％。疾病控制率（PR＋SD）为57．1％。获PR的12例患者中位缓解时间为6个月（3—78个月）；获SD的20例患者中位稳定时间为4个月（2～24个月）。吉非替尼治疗获疾病控制者（PR＋SD）与无效者（PD）相比，其中位生存时间明显延长（P=0．000）。痤疮样皮疹发生率占66．1％，多为轻、中度性。腹泻多为轻度。结论：吉非替尼治疗晚期NSCLC的疗效较好，毒副反应较轻，可以耐受。Objective：To explore the efficacy, side effects, toxicity and survival time of gefitinib for ITT patients with advavced non-small cell lung cancer（ NSCLC）. Methods： Retrospective analysis of the efficacy, side effects and toxicity and survival conditions for gefitinib in treatment of the 56 cases with advanced NSCLC and followed-up from January 2003 to December 2008. Resuits：Among of 56 cases with NSCLC in the treatment of gefitinib, partial response （PR） accounted for 21.4% ; stable disease （SD） accounted for 35.7% ; disease control rate（ PR ＋ SD）accounted for 57.1%. Median response time in 12 cases with PR was 6 months （range, 3-78） ; however, median response time in 20 cases with SD was 4 months （ range, 2-24）. Median survival time and overall survival were significantly improved on response patients （PR or SD） in comparison to nonresponse （PD） for gefitinib （P 〈 0. 001 ）. Skin rash accounted for 66. 1%. There was no significant relationship between rash severity degree and response. Diarrhea was mild and self-limited. Conclusion：This clinical observation suggested that gefetinib in treatment of patients with advanced NSCLC has better efficacy and well-tolerated toxicity.

关 键 词：非小细胞肺癌 分子靶向治疗 吉非替尼 生存分析 

分 类 号：R730.53[医药卫生—肿瘤] R734.2[医药卫生—临床医学]